Michal Yalon-Oren - Concepedia

Author

Michal Yalon-Oren

Children's Hospital Colorado

Also Known As

Michal Yalon-Oren

Publications

613

Citations

H-Index

Concepts

All Affiliations

Children's Hospital Colorado Children's Hospital of Philadelphia Institut Gustave Roussy Columbia University Irving Medical Center St. Jude Children's Research Hospital

About

Michal Yalon-Oren is an author at Children's Hospital Colorado specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	389
2	Pathology	4	4	389
3	Health Sciences	3	3	65
4	Diagnostic Sciences	2	2	26
5	Radiation Medicine	1	1	13

Michal Yalon-Oren

Publications

605

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, The Lancet Oncology Interim AnalysisLymphoid NeoplasiaSurgical OncologyMedicineMelanoma	2019	324
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency Anirban Das, Sumedha Sudhaman, Daniel A. Morgenstern, Nature Medicine	2022	132
DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells Jiil Chung, Yosef E. Maruvka, Sumedha Sudhaman, Cancer Discovery	2020	84
Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study Sara Khan, Palma Solano‐Páez, Tannu Suwal, The Lancet Child & Adolescent Health Multi-layered RosettesNeuro-oncologyTumoral PathologyGliomaTumor Heterogeneity	2021	39
Phase 1/2 KEYNOTE-051 study of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1<sup>+</sup> advanced, relapsed, or refractory solid tumor or lymphoma. Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, Journal of Clinical Oncology PathologyImmunotherapyRefractory Solid TumorTranslational MedicineRadiation Medicine	2017	13
KEYNOTE-051: An update on the phase 2 results of pembrolizumab (pembro) in pediatric patients (pts) with advanced melanoma or a PD-L1–positive advanced, relapsed or refractory solid tumor or lymphoma. Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, Journal of Clinical Oncology PathologyPharmacotherapyImmunotherapyRefractory Solid TumorProlonged Pr	2018	13

Page 1